Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
101 hedge funds and large institutions have $101M invested in Endocyte, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 27 reducing their positions, and 17 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 27
0% more funds holding
Funds holding: 101 → 101 (0)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
20% less capital invested
Capital invested by funds: $126M → $101M (-$25.6M)
52% less call options, than puts
Call options by funds: $3.38M | Put options by funds: $6.98M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.48M |
| 2 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$2.36M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.6M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.43M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$915K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$12.2M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$5.72M |
| 3 |
PAAMCP
Pacific Alternative Asset Management Company (PAAMCO)
Irvine,
California
|
-$3.5M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.07M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.02M |
ECYT Hedge Fund Activity: Q3 2014 in Review
101 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2014, worth a combined $101M — down 20% from $126M a quarter earlier.
Fund positioning in ECYT was balanced in Q3 2014: 17 funds opened new positions, 17 closed out, 33 added to existing stakes and 27 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.48M. The largest seller was BB Biotech, cutting an estimated $12.2M.
- 101 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $101M of Endocyte, Inc. Common Stock stock for Q3 2014, down 20% quarter-over-quarter.
- 17 funds opened new Endocyte, Inc. Common Stock positions in Q3 2014 and 17 closed out, a net change of 0 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q3 2014 was Millennium Management, an estimated $3.48M added.
- The largest Endocyte, Inc. Common Stock seller in Q3 2014 was BB Biotech, an estimated $12.2M sold.
Based on aggregated 13F filings for Q3 2014.